| Date |
 |
Title |
|
|
|
|
| 7/30/2010 |
|
Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference |
|
|
|
| 7/29/2010 |
|
Anadys Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights |
|
|
|
| 7/29/2010 |
|
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24 |
|
|
|
| 7/22/2010 |
|
Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results |
|
|
|
| 5/26/2010 |
|
Anadys Pharmaceuticals Announces $12.5 Million Registered Direct Offering |
|
|
|
| 5/26/2010 |
|
Anadys Retains Lazard as Strategic Advisor |
|
|
|
| 5/21/2010 |
|
Anadys Announces Completed 12-Week Results From Phase II Combination Study |
|
|
|
| 4/27/2010 |
|
Anadys Pharmaceuticals Reports First Quarter 2010 Financial Results and Highlights |
|
|
|
| 4/20/2010 |
|
Anadys Pharmaceuticals to Report First Quarter 2010 Financial Results |
|
|
|
| 4/15/2010 |
|
72% of Patients Receiving ANA598 in Phase II Combination Study with Interferon and Ribavirin Achieve Undetectable Levels of Virus at Week Eight |
|
|
|
| 3/29/2010 |
|
Anadys Announces Two ANA598 Presentations to be Made at the EASL Annual Meeting in April |
|
|
|
| 3/25/2010 |
|
Anadys Pharamaceuticals to Present at the CanAccord Adams Hepatitis C Conference |
|
|
|
| 3/9/2010 |
|
Anadys Pharamaceuticals to Present at the ROTH OC Stock Growth Conference |
|
|
|
| 3/1/2010 |
|
Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference |
|
|
|
| 2/24/2010 |
|
ANA598 Demonstrates 73% cEVR in Combination with Interferon and Ribavirin |
|
|
|
| 2/24/2010 |
|
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results and Highlights |
|
|
|
| 2/17/2010 |
|
Anadys Pharamaceuticals to Report Fourth Quarter and Year End 2009 Financial Results |
|
|
|
| 2/2/2010 |
|
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference |
|
|
|
| 1/22/2010 |
|
ANADYS PHARMACEUTICALS PROVIDES PROGRESS UPDATE |
|
|
|
| 12/17/2009 |
|
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID |
|
|
|
| 11/24/2009 |
|
Anadys Pharamaceuticals to Present at the Piper Jaffray Healthcare Conference |
|
|
|
| 10/29/2009 |
|
Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights |
|
|
|
| 10/22/2009 |
|
Anadys Pharmaceuticals To Report Third Quarter 2009 Financial Results |
|
|
|
| 10/20/2009 |
|
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences |
|
|
|
| 9/28/2009 |
|
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference |
|
|
|
| 9/9/2009 |
|
Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 |
|
|
|
| 9/3/2009 |
|
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences |
|
|
|
| 8/11/2009 |
|
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis Patients |
|
|
|
| 7/30/2009 |
|
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination with Interferon-Alpha and Ribavirin in HCV Patients |
|
|
|
| 7/30/2009 |
|
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Highlights |
|
|
|
| 7/23/2009 |
|
Anadys Pharmaceuticals, Inc. To Report Second Quarter 2009 Financial Results |
|
|
|
| 6/4/2009 |
|
Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering |
|
|
|
| 6/4/2009 |
|
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 |
|
|
|
| 4/23/2009 |
|
ANA598 Demonstrates Potent Antiviral Activity at All Dose Levels in Completed Phase Ib Study in Hepatitis C Patients |
|
|
|
| 4/23/2009 |
|
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights |
|
|
|
| 4/17/2009 |
|
Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results |
|
|
|
| 3/31/2009 |
|
Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference |
|
|
|
| 3/26/2009 |
|
Anadys Pharmaceuticals to Present at Future Leaders in Biotech industry |
|
|
|
| 3/25/2009 |
|
Anadys Pharmaceuticals to Present at the Citi Biotech Day |
|
|
|
| 3/12/2009 |
|
Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference |
|
|
|
| 2/26/2009 |
|
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights |
|
|
|
| 2/19/2009 |
|
Anadys Pharmaceuticals to Present Fourth Quarter and Year End Financial Results |
|
|
|
| 2/9/2009 |
|
Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference |
|
|
|
| 2/2/2009 |
|
Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference |
|
|
|
| 1/8/2009 |
|
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients |
|
|
|
| 12/1/2008 |
|
ANA598 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection |
|
|
|
| 11/25/2008 |
|
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference |
|
|
|
| 11/20/2008 |
|
Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference |
|
|
|
| 11/4/2008 |
|
Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference |
|
|
|
| 11/1/2008 |
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results For ANA598 in Healthy Volunteers |
|
|
|
| 10/30/2008 |
|
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients |
|
|
|
| 10/28/2008 |
|
Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study |
|
|
|
| 10/23/2008 |
|
Anadys Pharmaceuticals Reports Third Quarter |
|
|
|
| 10/20/2008 |
|
Anadys Pharmaceuticals to Present at Biocom Investor Conference 2008 |
|
|
|
| 10/16/2008 |
|
Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results |
|
|
|
| 9/30/2008 |
|
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference |
|
|
|
| 9/24/2008 |
|
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients |
|
|
|
| 9/8/2008 |
|
Anadys Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit |
|
|
|
| 8/1/2008 |
|
Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference |
|
|
|
| 7/30/2008 |
|
Anadys Pharmaceuticals Reports Second Quarter |
|
|
|
| 7/23/2008 |
|
Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results |
|
|
|
| 6/2/2008 |
|
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598 |
|
|
|
| 5/12/2008 |
|
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences |
|
|
|
| 4/30/2008 |
|
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights |
|
|
|
| 4/23/2008 |
|
Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results |
|
|
|
| 4/17/2008 |
|
Anadys Pharmaceuticals Presents Data on ANA598, A Nonnucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research |
|
|
|
| 4/2/2008 |
|
Anadys Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference |
|
|
|
| 3/11/2008 |
|
Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference |
|
|
|
| 2/28/2008 |
|
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients |
|
|
|
| 2/27/2008 |
|
Anadys Pharmaceuticals to Present at the Susquehanna Significant Options in Healthcare Conference |
|
|
|
| 2/20/2008 |
|
Anadys Pharmaceuticals Reports Fourth Quarter and Year-end 2007 Financial Results and Highlights |
|
|
|
| 2/14/2008 |
|
Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2007 Financial Results |
|
|
|
| 2/5/2008 |
|
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference |
|
|
|
| 1/4/2008 |
|
Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference |
|
|
|
| 11/21/2007 |
|
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference |
|
|
|
| 11/1/2007 |
|
AnadyS Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights |
|
|
|
| 10/30/2007 |
|
Anadys Pharmaceuticals to Present at the Acumen Biofin Rodman & Renshaw Healthcare Conference |
|
|
|
| 10/24/2007 |
|
Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results |
|
|
|
| 10/3/2007 |
|
Anadys Pharmaceuticals to Present at BIO Investorforum 2007 |
|
|
|
| 9/11/2007 |
|
Anadys Pharmaceuticals Presents Preclinical Results on ANA598, A Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses |
|
|
|
| 8/24/2007 |
|
Anadys Pharmaceuticals Appoints Steve Worland, PH.D. as President and Chief Executive Officer |
|
|
|
| 8/1/2007 |
|
Anadys Pharmaceuticals Announces Strategic Restructuring and Reports Second Quarter 2007 Financial Results |
|
|
|
| 7/26/2007 |
|
Development Discontinued for ANA975, an Early Stage Compound for Treatment of Hepatitis C Virus Infection |
|
|
|
| 7/25/2007 |
|
Anadys Pharmaceuticals to Report Second Quarter 2007 Financial Results |
|
|
|
| 6/20/2007 |
|
Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase,as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection |
|
|
|
| 6/4/2007 |
|
Anadys Pharmaceuticals Announces Promotion of Carol G. Gallagher, Pharm. D., to Senior Vice President, Corporate Development and Commercial Affairs |
|
|
|
| 5/3/2007 |
|
Anadys Pharmaceuticals Reports First Quarter 2007 Financial Results |
|
|
|
| 5/2/2007 |
|
Anadys Presents Results From Its NS5b HCV Program at International Conference on Antiviral Research |
|
|
|
| 4/27/2007 |
|
Anadys Pharmaceuticals to Report First Quarter 2007 Financial Results |
|
|
|
| 4/17/2007 |
|
Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells |
|
|
|
| 4/13/2007 |
|
ANA380 Exhibits Activity In Vitro Against Multiple Clinically ANA380 Exhibits Activity In Vitro Against Multiple Clinically |
|
|
|
| 3/22/2007 |
|
Anadys Pharmaceuticals to Present at BioCentury's Future Leaders in the Biotech Industry Conference |
|
|
|
| 3/6/2007 |
|
Anadys Pharmaceuticals to Present at the Cowen & Company's 27th Annual Healthcare Conference |
|
|
|
| 2/26/2007 |
|
Anadys Pharmaceuticals to Present at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference |
|
|
|
| 2/22/2007 |
|
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2006 Financial Results |
|
|
|
| 2/15/2007 |
|
Anadys Pharmaceuticals to Report Fourth Quarter & Year-End 2006 Financial Results |
|
|
|
| 2/7/2007 |
|
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference |
|
|
|
| 1/17/2007 |
|
John Z. Sullivan-Bolyai, M.D., MPH, Joins Anadys Pharmaceuticals as Vice President, Clinical Affairs |
|
|
|
| 12/12/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to Webcast of Anti-Infectives Panel Discussion at RBC Capital Markets Healthcare Conference |
|
|
|
| 11/27/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to Webcasts of Two Upcoming Presentations |
|
|
|
| 11/20/2006 |
|
Anadys Pharmaceuticals Names Lawrence C. Fritz, Ph.D., as President and Chief Executive Officer |
|
|
|
| 11/13/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to Webcasts of Five Upcoming Presentations |
|
|
|
| 11/7/2006 |
|
ANA975 in a New 13-Week Pre-Clinical Toxicology Study Using Crystalline Form |
|
|
|
| 11/2/2006 |
|
Anadys Pharmaceuticals Reports Third Quarter 2006 Financial Results |
|
|
|
| 10/27/2006 |
|
Anadys Pharmaceuticals to Report Third Quarter 2006 Financial Results |
|
|
|
| 10/12/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to a Webcast of a Presentation at the BIO Investor Forum |
|
|
|
| 9/25/2006 |
|
Anadys Pharmaceuticals Appoints James T. Glover as Senior Vice President of Operations and Chief Financial Officer |
|
|
|
| 9/7/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to a Webcast of a Presentation at the Bear Stearns 19th Annual Healthcare Conference in New York |
|
|
|
| 8/8/2006 |
|
Anadys Pharmaceuticals Reports Second Quarter 2006 Financial Results |
|
|
|
| 8/2/2006 |
|
Anadys Pharmaceuticals to Report Second Quarter 2006 Financial Results |
|
|
|
| 7/11/2006 |
|
James L. Freddo, M.D., Joins Anadys Pharmaceuticals as Chief Medical Officer |
|
|
|
| 7/6/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to a Webcast of a Presentation at the C.E. Unterberg, Towbin Emerging Growth Conference in New York |
|
|
|
| 6/26/2006 |
|
Anadys Pharmaceuticals Suspends Dosing of ANA975 in Hepatitis C Clinical Trial Pending Further Assessment of 13-Week Pre-Clinical Toxicology Studies |
|
|
|
| 6/15/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to a Webcast of a Presentation at the Piper Jaffray Healthcare Conference in London, England |
|
|
|
| 6/14/2006 |
|
Anadys Pharmaceuticals' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President & CEO by Year-End to Join San Diego VC Firm |
|
|
|
| 6/6/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to Webcasts of Presentations at Two Upcoming Conferences |
|
|
|
| 5/24/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to a Webcast of Its Presentation at the Bear Stearns Biotech Boston Confab |
|
|
|
| 5/12/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to a Webcast of Its Presentation at the Bank of America Health Care Conference 2006 |
|
|
|
| 5/9/2006 |
|
Anadys Pharmaceuticals Reports First Quarter 2006 Financial Results |
|
|
|
| 5/2/2006 |
|
Anadys Pharmaceuticals to Report First Quarter 2006 Financial Results |
|
|
|
| 4/26/2006 |
|
Completion of ANA380 Dosing in Phase II Clinical Trial Confirms Robust Activity Against Lamivudine-Resistant Hepatitis B Virus |
|
|
|
| 4/25/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to Webcast of Its Presentation at the Deutsche Bank 31st Annual Healthcare Conference |
|
|
|
| 4/10/2006 |
|
Anadys Pharmaceuticals Appoints Robert Schooley, M.D., to its Clinical and Scientific Advisory Board |
|
|
|
| 4/5/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at the BIO 2006 Annual International Convention |
|
|
|
| 3/22/2006 |
|
Carol G. Gallagher, Pharm. D., to Join Anadys Pharmaceuticals as Vice President, Commercial Affairs |
|
|
|
| 3/20/2006 |
|
Anadys Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at the Bear Stearns Biotech Confab |
|
|
|
| 3/1/2006 |
|
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences |
|
|
|
| 2/23/2006 |
|
Anadys Pharmaceuticals to Report Fourth Quarter & Year-End 2005 Financial Results |
|
|
|
| 2/23/2006 |
|
ANADYS PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2005 FINANCIAL RESULTS |
|
|
|
| 2/22/2006 |
|
Michael Adam, Ph.D. to Join Anadys Pharmaceuticals as Senior Vice President, Development Operations |
|
|
|
| 2/14/2006 |
|
Robust Viral Load Reduction Successfully Achieved in Phase II Clinical Trial of ANA380 in Lamivudine-Resistant, Hepatitis B Patients |
|
|
|
| 2/10/2006 |
|
Anadys Pharmaceuticals to Present at the BIO CEO & Investor 2006 Conference |
|
|
|
| 2/1/2006 |
|
Anadys Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference |
|
|
|
| 1/10/2006 |
|
Anadys Pharmaceuticals Appoints Frank V. Chisari, M.D., to Its Clinical & Scientific Advisory Board |
|
|
|
| 1/5/2006 |
|
Anadys Pharmaceuticals to Present at the 24th Annual JP Morgan Healthcare Conference |
|
|
|
| 12/22/2005 |
|
Anadys Pharmaceuticals to Initiate 28-Day Clinical Trial of ANA975 in Patients With Chronic Hepatitis C |
|
|
|
| 12/19/2005 |
|
Anadys Pharmaceuticals Announces Two Executive Advances |
|
|
|
| 12/15/2005 |
|
George A. Scangos, Ph.D., Named Chairman of the Board of Anadys Pharmaceuticals |
|
|
|
| 12/13/2005 |
|
Anadys Pharmaceuticals Selects a Novel Oral Toll-Like Receptor Ligand as Drug Development Candidate for Cancer |
|
|
|
| 11/22/2005 |
|
Anadys Pharmaceuticals to Present at Lazard Capital Markets Annual Life Sciences Conference |
|
|
|
| 11/15/2005 |
|
Anadys Pharmaceuticals to be Added to the NASDAQ Biotechnology Index (NBI) |
|
|
|
| 11/14/2005 |
|
ANA975 Phase I Clinical Data to Be Presented at the American Association of the Study of Liver Diseases (AASLD) Annual Meeting |
|
|
|
| 11/10/2005 |
|
Anadys Pharmaceuticals to Present at Credit Suisse First Boston Annual Healthcare Conference |
|
|
|
| 11/4/2005 |
|
Anadys Pharmaceuticals to Present at SG Cowen & Co.'S 6th Annual Global Health Care Conference |
|
|
|
| 11/3/2005 |
|
Anadys Pharmaceuticals to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference |
|
|
|
| 11/1/2005 |
|
Anadys Pharmaceuticals Reports Third Quarter 2005 Financial Results |
|
|
|
| 10/18/2005 |
|
Anadys Pharmaceuticals to Report Third Quarter Financial Results on November 1, 2005 |
|
|
|
| 10/13/2005 |
|
Anadys Pharmaceuticals to Present at BIO Investor Forum and Participate in a Panel Workshop On Hepatitis C |
|
|
|
| 9/20/2005 |
|
Anadys Pharmaceuticals to Present at UBS Global Life Sciences Conference |
|
|
|
| 9/12/2005 |
|
Anadys Pharmaceuticals to Present at Bear Stearns' 18th Annual |
|
|
|
| 9/7/2005 |
|
Mark G. Foletta to Join Anadys Pharmaceuticals' Board of Directors |
|
|
|
| 9/2/2005 |
|
Anadys Pharmaceuticals to Present at BioCentury's 12th Anniversary Newsmakers in the Biotech Industry Conference |
|
|
|
| 8/23/2005 |
|
Anadys Pharmaceuticals Announces Publication of Clinical Study of Isatoribine in Chronic Hepatitis C Demonstrating Proof of Concept |
|
|
|
| 8/18/2005 |
|
Anadys Pharmaceuticals Announces FDA Acceptance of IND Application for ANA975 |
|
|
|
| 8/11/2005 |
|
Anadys Pharmaceuticals Announces Closing of Public Offering of Common Stock |
|
|
|
| 8/8/2005 |
|
Anadys Pharmaceuticals Announces Exercise in Full of Over-Allotment Option By Underwriters |
|
|
|
| 8/4/2005 |
|
Anadys Pharmaceuticals Announces Pricing of Common Stock Offering |
|
|
|
| 8/2/2005 |
|
Anadys Pharmaceuticals Reports Second Quarter 2005 Financial Results |
|
|
|
| 8/1/2005 |
|
Anadys Pharmaceuticals Announces Proposed Offering of Common Stock |
|
|
|
| 7/7/2005 |
|
Anadys Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Exclusive Collaboration With Novartis |
|
|
|
| 6/14/2005 |
|
Anadys Pharmaceuticals to Present at BIO 2005 Business Forum |
|
|
|
| 6/10/2005 |
|
Anadys Pharmaceuticals President and CEO Establishes 10b5-1 Trading Plan |
|
|
|
| 6/2/2005 |
|
Anadys Pharmaceuticals Announces Exclusive Collaboration With Novartis to Develop and Commercialize ANA975 and Additional TLR7-Based Therapeutics for Hepatitis C and Hepatitis B |
|
|
|
| 5/19/2005 |
|
Anadys Pharmaceuticals to Present at Needham Biotechnology Conference on May 26, 2005 |
|
|
|
| 5/17/2005 |
|
Anadys Pharmaceuticals to Present at UBS Global Pharmaceuticals Conference on May 24, 2005 |
|
|
|
| 5/5/2005 |
|
Anadys Pharmaceuticals Reports First Quarter 2005 Financial Results |
|
|
|
| 5/3/2005 |
|
Anadys Pharmaceuticals Announces Senior Management Member Resignation |
|
|
|
| 4/28/2005 |
|
Anadys Pharmaceuticals to Report First Quarter Financial Results on May 5, 2005 |
|
|
|
| 4/22/2005 |
|
Anadys Pharmaceuticals Files Shelf Registration Statement |
|
|
|
| 4/18/2005 |
|
Anadys Pharmaceuticals and LG Life Sciences Report Activity Against Lamivudine-Resistant Strains in Phase II Clinical Trial of ANA380 for Hepatitis B |
|
|
|
| 3/31/2005 |
|
Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference On April 7, 2005 |
|
|
|
| 3/29/2005 |
|
Anadys Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference |
|
|
|
| 3/24/2005 |
|
BIOCOM Announces New Board Officers and Board Members |
|
|
|
| 3/8/2005 |
|
Anadys Pharmaceuticals to Present at SG Cowen & Co. Health Care Conference on March 15, 2005 |
|
|
|
| 2/25/2005 |
|
Anadys Pharmaceuticals to Present at Wells Fargo Securities Healthcare Conference on March 1, 2005 |
|
|
|
| 2/23/2005 |
|
Anadys Pharmaceuticals Appoints Vice President of Finance |
|
|
|
| 2/17/2005 |
|
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2004 Financial Results |
|
|
|
| 2/16/2005 |
|
Anadys Pharmaceuticals to Present at BIO CEO & Investor Conference on February 23, 2005 |
|
|
|
| 2/10/2005 |
|
Anadys Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results on February 17, 2005 |
|
|
|
| 2/2/2005 |
|
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA975, an Oral Prodrug of Isatoribine for Hepatitis C |
|
|
|
| 1/21/2005 |
|
Anadys Pharmaceuticals to Present at Piper Jaffray Health Care Conference on January 27, 2005 |
|
|
|
| 12/13/2004 |
|
Anadys Pharmaceuticals and LG Life Sciences Report Positive Data From Phase II Clinical Trial of ANA380 in Patients With Lamivudine-Resistant Hepatitis B Virus Infection |
|
|
|
| 12/2/2004 |
|
Anadys Pharmaceuticals Appoints Douglas Richman, M.D. as Chairman of Clinical and Scientific Advisory Board |
|
|
|
| 11/12/2004 |
|
Anadys Pharmaceuticals to Present at Credit Suisse First Boston Healthcare Conference on November 17, 2004 |
|
|
|
| 11/11/2004 |
|
Anadys Pharmaceuticals to Present at SG Cowen & Co. Global Health Care Conference on November 16, 2004 |
|
|
|
| 11/9/2004 |
|
Anadys Pharmaceuticals Reports Third Quarter 2004 Financial Results |
|
|
|
| 11/3/2004 |
|
Anadys Pharmaceuticals Reports Hepatitis C Viral Load Reduction in Completed Phase IB Clinical Trial of Isatoribine |
|
|
|
| 11/1/2004 |
|
Anadys Pharmaceuticals and LG Life Sciences Report Results From Completed Phase I/II Clinical Trial of ANA380 (LB80380) for Hepatitis B |
|
|
|
| 10/26/2004 |
|
Anadys Pharmaceuticals To Announce Third Quarter Financial Results and Clinical Development Plans on November 9, 2004 |
|
|
|
| 10/20/2004 |
|
Anadys Pharmaceuticals to Present at Rodman & Renshaw Techvest Annual Healthcare Conference on October 27, 2004 |
|
|
|
| 10/14/2004 |
|
Anadys Pharmaceuticals to Report New Clinical Data From Hepatitis C and Hepatitis B Programs at Upcoming AASLD Annual Meeting |
|
|
|
| 10/8/2004 |
|
Anadys Pharmaceuticals To Present at BIO Emerging Company Investor Forum on October 15, 2004 |
|
|
|
| 10/6/2004 |
|
Anadys Pharmaceuticals Announces Executive Promotions in R&D |
|
|
|
| 9/23/2004 |
|
Anadys Pharmaceuticals to Present at UBS Global Life Sciences Conference on September 29, 2004 |
|
|
|
| 9/21/2004 |
|
Anadys Pharmaceuticals to Receive Up to $1.2 Million From NIH for Development of Novel Antibacterials |
|
|
|
| 9/14/2004 |
|
Anadys Pharmaceuticals and LG Life Sciences Announce Phase II Clinical Trial of ANA380 (LB80380) in Patients with Drug-Resistant Hepatitis B Virus Infection |
|
|
|
| 9/9/2004 |
|
Anadys Pharmaceuticals and Aphoenix Announce Drug Discovery Collaboration |
|
|
|
| 8/25/2004 |
|
Anadys Pharmaceuticals Strengthens Board of Directors with Addition of Douglas Williams, Ph.D. |
|
|
|
| 8/10/2004 |
|
Anadys Pharmaceuticals Appoints Steven Holtzman to Board of Directors |
|
|
|
| 8/5/2004 |
|
Anadys Pharmaceuticals Reports Second Quarter 2004 Financial Results |
|
|
|
| 7/29/2004 |
|
Anadys Pharmaceuticals Enters New Drug Discovery Collaboration with Roche; Second Alliance Builds on Success of Initial Collaboration |
|
|
|
| 7/29/2004 |
|
Anadys Pharmaceuticals to Announce Second Quarter Financial Results on August 5, 2004 |
|
|
|
| 6/14/2004 |
|
Anadys Pharmaceuticals to Present at Third Annual Needham Biotechnology Conference |
|
|
|
| 6/3/2004 |
|
Anadys Pharmaceuticals to Present at BIO 2004 Annual Convention |
|
|
|
| 6/2/2004 |
|
Anadys Pharmaceuticals Announces Move to Facility Located in the Torrey Mesa Area, San Diego, California; State-of-the-Art, Former Syngenta Facility to Serve as New Base |
|
|
|
| 5/26/2004 |
|
Anadys Pharmaceuticals Announces Selection of ANA975 as a Development Candidate for Front-Line Treatment Of Chronic Hepatitis C |
|
|
|
| 5/13/2004 |
|
Anadys Pharmaceuticals Reports First Quarter 2004 Financial Results |
|
|
|
| 5/11/2004 |
|
Anadys Pharmaceuticals and LG Life Sciences Announce Completion of Phase I/IIa Clinical Trial of ANA380 -LB80380-in Patients Chronically Infected with Hepatitis B Virus |
|
|
|
| 5/6/2004 |
|
Anadys Pharmaceuticals to Announce First Quarter 2004 Financial Results on May 13, 2004 |
|
|
|
| 4/26/2004 |
|
Anadys Pharmaceuticals Announces Exercise of Underwriters' Over-Allotment Option |
|
|
|
| 4/19/2004 |
|
Anadys Pharmaceuticals and LG Life Sciences Enter into Joint Development and License Agreement for LB80380 (ANA380), a Phase II Hepatitis B Compound |
|
|
|
| 3/25/2004 |
|
Anadys Pharmaceuticals Announces Initial Public Offering |
|
|
|
| 3/2/2004 |
|
Anadys Announces Executive Promotion and Appointment of New Regulatory Affairs Post |
|
|
|
| 2/19/2004 |
|
Anadys Announces Initiation Of Clinical Trial Of ANA971, An Orally Administered Prodrug Of Isatoribine |
|
|
|
| 2/9/2004 |
|
Anadys Achieves Research Milestone in Drug Discovery Collaboration With Amgen |
|
|
|
| 1/5/2004 |
|
Anadys Forms Drug Discovery Collaboration with Daiichi |
|
|
|
